MTMasakazu Toi

Masakazu Toi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Masakazu Toi has a total of 74 co-authors. Here are the top co-authors by number of shared publications:

  • Hiroko Bando

    Komagome Hospital

    6 shared publications
  • Masahiro Takada

    Department of Breast Surgery, Kansai Medical University, Hirakata, Japan

    3 shared publications
  • N Funata

    Department of Pathology, Tokyo Metropolitan Komagome Hospital, Tokyo Metropolitan Cancer and Infectious Disease Center, 3-18-22, Honkomagome Bunkyo-ku, Tokyo 113-8677, Japan

    3 shared publications
  • Shigehira Saji

    Komagome Hospital

    3 shared publications
  • H Bando

    Department of Surgery, Tokyo Metropolitan Komagome Hospital, Tokyo Metropolitan Cancer and Infectious Disease Center, 3-18-22, Honkomagome Bunkyo-ku, Tokyo 113-8677, Japan

    2 shared publications
  • S Horiguchi

    Department of Pathology, Tokyo Metropolitan Komagome Hospital, Tokyo Metropolitan Cancer and Infectious Disease Center, 3-18-22, Honkomagome Bunkyo-ku, Tokyo 113-8677, Japan

    2 shared publications

Latest Publications

  • Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival

    by Masakazu Toi, Seigo Nakamura, Katsumasa Kuroi, Hiroji Iwata, Shinji Ohno, Norikazu Masuda, Mikihiro Kusama, Kosuke Yamazaki, Kazuhumi Hisamatsu, Yasuyuki Sato, et al.

    Purpose This multicenter phase II study examined the impact of pathological effect on survival after preoperative chemotherapy in Japanese women with early stage breast cancer. Patients and methods Prior to surgery, patients received four cycles of FEC (fluorouracil 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2 q3w) followed by four cycles of docetaxel (75 mg/m2 q3w). Primary endpoint was 3 year disease free survival (DFS) stratified by the absence or presence of Quasi-pCR (QpCR; absence of invasive tumor or only focal residual tumor cells). Secondary endpoints were predictors for QpCR, clinical response, breast conservation rate, and safety. Results Between June 2002 and June 2004, 202 women were enrolled. Among 191 assessable patients, 25% achieved QpCR. With 40 months median follow-up, 3 year DFS was estimated at 91% for all patients. 3 year DFS for patients with QpCR was 98% vs. 89% without QpCR (hazard ratio 0.38 [95% Confidence Interval 0.09–0.84], P = 0.0134). HER2 status and response to FEC were independent predictors of QpCR. The overall clinical response was 75%; 85% of patients achieved breast conservation. Grade 3/4 neutropenia was the most common adverse event, observed in 44% and 35% of patients during FEC and docetaxel, respectively. Treatment related side effects were manageable; there were no treatment related fatalities. Conclusion FEC followed by docetaxel is an active and manageable preoperative regimen for women with early stage breast cancer. QpCR following preoperative chemotherapy predicts favorable DFS. HER2 overexpression and clinical response to FEC predict QpCR.


  • Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo

    by Zahidunnabi Dewan, Hiroshi Terunuma, Masahiro Takada, Yuetsu Tanaka, Hiroyuki Abe, Tetsutaro Sata, Masakazu Toi, Naoki Yamamoto

    Natural killer (NK) cells play a central role in host defense against tumor and virus-infected cells. Direct role of NK cells in tumor growth and metastasis remains to be elucidated. We here demonstrated that NOD/SCID/γcnull (NOG) mice lacking T, B and NK cells inoculated with breast cancer cells were efficient in the formation of a large tumor and spontaneous organ-metastasis. In contrast, breast cancer cells produced a small tumor at inoculated site in T and B cell knock-out NOD/SCID mice with NK cells while completely failed to metastasize into various organs. Immunosupression of NOD/SCID by treatment with an anti-murine TM-β1 antibody, which transiently abrogates NK cell activity in vivo, resulted in enhancing tumor formation and organ-metastasis in comparison with non-treated NOD/SCID mice. Activated NK cells inhibited tumor growth in vivo. The rapid and efficient engraftment of the breast cancer cells in NOG mice suggests that this new animal model could provide a unique opportunity to understand and investigate the mechanism of tumor cell growth and metastasis. Our results suggest that NK cells play an important role in cancer growth and metastasis and could be a promising immunotherapeutic strategy against cancer either alone or in combination with conventional therapy.


  • Cost-effective treatment options in first-line therapy for advanced breast cancer in Japan

    by Masahide Kondo, Masakazu Toi

    Concern regarding the economic aspect of cancer care has been increasing in the face of mounting healthcare expenditure in Japan. The need, not only for effective, but also for efficient treatment options in breast cancer care have been recognized in a broader context. In clinical practice, treatment options in first-line therapy for advanced breast cancer have become similar to those in Western countries in the past 5 to 10 years in the context of so-called ‘evidence-based medicine’ employing clinical evidence; whereas evidence of cost-effectiveness has been less acknowledged. Limited economic evidence suggests that current Japanese practice in first-line hormonal therapy is cost-effective. However, the efficiency of other options, such as chemotherapy, remains unknown. The expanding use of an expensive molecular-targeting agent, trastuzumab, has great implications for a treatment algorithm for breast cancer as well as for cost-effectiveness of care. Trastuzumab, of which use in first-line therapy was not found to be cost-effective in Western countries, is expected to be used for a number of HER2-overexpressing primary breast cancers in Japan. The extension of indication of this single agent would increase national healthcare expenditure by 0.1%. The authors believe explicit discussion on value for money of new expensive drugs would be unavoidable, not only among health policy makers, but also leading breast cancer specialists in Japan in the near future.


  • Trastuzumab: updates and future issues

    by Masakazu Toi, Kazumi Horiguchi, Hiroko Bando, Shigehira Saji, Louis W. C. Chow

    Trastuzumab has had an enormous impact on the clinical management of breast cancer: the survival of Her-2-positive metastatic breast cancer patients has improved significantly and tumor Her-2 status has been built into the decision-making tree for primary breast cancer patients. Several pioneering studies have shown that trastuzumab-combined chemotherapy elicits high levels of pathological complete response in the neoadjuvant setting. Currently, therefore, a more precise understanding of the mechanisms of therapeutic response is needed so that trastuzumab-based therapies can be optimized more individually. It might also be important to investigate, with greater depth, the interaction between the Her-axis and the hormone-axis. This short review describes and discusses these topics.


  • Open Access

    Late Phase II Clinical Study of Vinorelbine Monotherapy in Advanced or Recurrent Breast Cancer Previously Treated with Anthracyclines and Taxanes

    by Masakazu Toi, Toshiaki Saeki, Kenjiro Aogi, Muneaki Sano, Kiyohiko Hatake, Taro Asaga, Yutaka Tokuda, Shoshu Mitsuyama, Morihiko Kimura, Tadashi Kobayashi, et al.

    Background: At present, it is one of the most important issues for the treatment of breast cancer to develop the standard therapy for patients previously treated with anthracyclines and taxanes. With the objective of determining the usefulness of vinorelbine monotherapy in patients with advanced or recurrent breast cancer after standard therapy, we evaluated the efficacy and safety of vinorelbine in patients previously treated with anthracyclines and taxanes. Methods: Vinorelbine was administered at a dose level of 25 mg/m2 intravenously on days 1 and 8 of a 3 week cycle. Patients were given three or more cycles in the absence of tumor progression. A maximum of nine cycles were administered. Results: The response rate in 50 evaluable patients was 20.0% (10 out of 50; 95% confidence interval, 10.0–33.7%). Responders plus those who had minor response (MR) or no change (NC) accounted for 58.0% [10 partial responses (PRs) + one MR + 18 NCs out of 50]. The Kaplan–Meier estimate (50% point) of time to progression (TTP) was 115.0 days. The response rate in the visceral organs was 17.3% (nine PRs out of 52). The major toxicity was myelosuppression, which was reversible and did not require discontinuation of treatment. Conclusion: The results of this study show that vinorelbine monotherapy is useful in patients with advanced or recurrent breast cancer previously exposed to both anthracyclines and taxanes.


  • Open Access

    Translational research in breast cancer

    by Masakazu Toi, Yuji Takebayashi, Louis W. Chow

    Translational research (TR) involves both the development of novel diagnostics and novel therapeutics. These two major developmental areas are often associated with each other and these associations...